AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?

The pharmaceutical industry is undergoing a transformation as older blockbuster drugs are replaced by newer, more innovative treatments. Investors must evaluate whether to invest in AbbVie Inc (NYSE:ABBV) or Eli Lilly and Co (NYSE:LLY), both of which operate in similar sectors but have distinct growth strategies. AbbVie specializes in immunology, oncology, and neuroscience therapies, with its revenue heavily concentrated in Skyrizi and Rinvoq, accounting for around 42% of sales in 2025.

To mitigate risks, the company acquired Apogee Therapeutics for approximately $10.9 billion. Revenue for FY 2025 reached nearly $61.2 billion, up 8.7% year-over-year, with net income close to $4.3 billion.

Eli Lilly's strategy focuses on high-growth areas like diabetes, obesity, and oncology. The company's GLP-1 drugs, Mounjaro and Zepbound, drive around 56% of its total revenue in 2025. Its recent partnerships with Incyte Corp (NASDAQ:INCY) and OmniAb Inc (NASDAQ:OABI) suggest strong growth prospects. In FY 2025, Lilly's revenue was nearly $65.2 billion, a 45% increase from the previous year, with net income around $20.6 billion.

Despite valuation metrics indicating higher future earnings estimates, both companies face challenges such as patent expirations, biosimilar competition, regulatory shifts, and supply chain risks. However, Eli Lilly's robust GLP-1 drug portfolio, including Zepbound and Mounjaro, presents a compelling case for long-term investors.